Beskrivning
| Land | Sverige |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2025-01-08 11:31:38
Inify Laboratories, a unique laboratory service that performs cancer diagnostics
within pathology, has entered into an agreement with the region of Västmanland
in Sweden on a pilot project with the goal of shortening waiting times for
results to patients with suspected prostate cancer.
Pathology in large parts of the Western world is under enormous pressure, with
an extensive mission and limited resources. One of the areas affected with long
and varying lead times is prostate cancer diagnostics. Most regions in Sweden
have challenges in reaching the goals that have been developed within the
framework of the cancer patient pathways. These stipulate that the patient
should receive the result within 11 days from the time of examination. For
urology clinics, delayed pathology reports mean that administrative time is
spent investigating when the results may be available and rescheduling patient
visits.
The goal of the pilot project is to shorten waiting times for patients while
making it easier for urologists to interpret the test results and plan
treatment.
"The unique aspect of this initiative is not the use of effective digital tools
and AI per se, but how the entire service, with high and consistent quality and
more efficient processes, benefits both doctors and patients - from day 1," says
Maria Holmberg, Sales and Marketing Manager at Inify Laboratories.
For more information, contact CEO Fredrik Palm, fredrik.palm@inify.com, or
visit https://www.inify.com (https://www.inify.com/sv/).
###
Inify Laboratories provides cancer diagnostics through ultramodern laboratory
services within pathology. It uses a fully digital, standardized and AI-
supported workflow to optimize quality and response times, initially within
prostate. The concept is scalable and can be extended to other diagnoses. The
service includes the whole chain of sample handling: from logistics, to sample
preparation, to reporting by a pathologist. The report is assisted by our own
AI, proven in clinical studies to have world-leading accuracy. The complete
workflow is supported by a tailor-made process control system. The company,
based in Sweden, became independent in 2022 through a spin-off from
ContextVision, with 40 years of experience within digital imaging for medical
applications. It is listed on Euronext Growth Oslo under the ticker INIFY.